Thrombin is a serine protease blood plasma protein used to convert fibrinogen into soluble fibrin during the blood coagulation process. It plays a crucial role in controlling excessive bleeding during surgeries and trauma treatments. Thrombin is widely utilized in hospitals, diagnostic centers, and clinics for applications such as coagulation assays, clotting factor tests, and defibrination of blood or plasma.
The market is witnessing significant growth due to the increasing number of road accidents, rising surgical procedures, and growing prevalence of inherited blood coagulation disorders. Healthcare professionals increasingly prefer thrombin products because of their strong procoagulant properties and effectiveness in managing severe blood loss during complex surgeries.
👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19580
The global thrombin market was valued at US$ 652.2 Mn in 2022 and is projected to reach US$ 1.1 Bn by the end of 2031, expanding at a CAGR of 6.1% from 2023 to 2031. Market growth is driven by rising road accidents, increasing prevalence of blood coagulation disorders, and growing investments in pharmaceutical R&D activities.
Analysis of Key Players in the Thrombin Market
The global thrombin market is highly competitive, with leading companies focusing on partnerships, product innovation, clinical trials, and research & development activities to strengthen their market position.
Key companies operating in the market include:
- Johnson & Johnson
- Pfizer, Inc.
- Mallinckrodt Pharmaceuticals
- Shanghai RAAS Blood Products Co., Ltd.
- Japan Blood Products Organization
- Mochida Pharmaceutical Co., Ltd.
- BIOFAC A/S
- Biomed-Lublin S.A.
- Hualan Biological Engineering, Inc.
- Other Prominent Players
These companies are investing significantly in advanced drug development methodologies and innovative treatment solutions to improve patient outcomes and expand their product portfolios.
Key Developments in Global Thrombin Market
- In April 2022, Bayer AG, a multinational pharmaceutical and biotechnology company, announced that its new thrombosis prevention drug, Asundexian, demonstrated positive results in a clinical study designed to assess its safety and determine the optimal dosage.
- In February 2022, CTI BioPharma, a leading company focusing on therapies for blood-related cancers, received approval from the United States Food and Drug Administration (FDA) for VONJO to treat adults with intermediate or high-risk primary or secondary myelofibrosis, including post-polycythemia Vera or post-essential thrombocythemia.
Analysts’ Viewpoint on the Global Thrombin Market
Industry analysts highlight that the rising number of road accidents and trauma cases globally is a major factor driving the demand for thrombin products. The increasing need for effective blood coagulation management during surgeries and emergency treatments is boosting adoption across healthcare facilities.
The growing prevalence of inherited blood disorders such as hemophilia, Von Willebrand disease, and thrombosis-related conditions is further accelerating market expansion. Pharmaceutical companies are increasingly investing in R&D activities to develop innovative thrombin-based therapies and improve treatment efficiency.
North America dominates the market due to advanced healthcare infrastructure, higher accident rates, and increased awareness regarding blood-related disorders. Meanwhile, emerging economies are witnessing growth due to improving healthcare accessibility and government investments in medical facilities.
👉 Discuss Implications for Your Industry or Do you want customize Report, Please Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19580
Key Player Strategies
⚙️ Product Innovation
Development of advanced thrombin-based therapies and surgical solutions
🌐 Strategic Partnerships
Collaborations with healthcare providers and research organizations
🏥 Clinical Research Expansion
Increasing investment in clinical trials and drug development
🔬 R&D Investments
Focus on innovative treatment options for blood coagulation disorders
🌍 Global Market Expansion
Expanding presence in developing healthcare markets
Market Segmentation
By Product Type
- Bovine Thrombin
- Human Thrombin
- Recombinant Thrombin
By Application
- Surgical Procedures
- Diagnostic Applications
- Research Applications
By End-user
- Hospitals
- Diagnostic Centers & Clinics
- Research Institutes
By Region
- North America – Advanced healthcare infrastructure and high treatment adoption
- Europe – Strong pharmaceutical and research activities
- Asia Pacific – Expanding healthcare investments and rising patient population
- Latin America
- Middle East & Africa
Regional Outlook
North America dominated the thrombin market in 2022 due to the increasing number of road accidents, advanced healthcare infrastructure, and rising prevalence of inherited blood disorders such as hemophilia. The availability of emergency medical facilities and high healthcare spending are supporting market growth across the region.
The United States remains a major contributor due to strong pharmaceutical R&D activities and growing demand for innovative coagulation therapies. According to industry statistics, the rising number of accident-related injuries requiring surgical intervention continues to fuel thrombin adoption.
Meanwhile, Asia Pacific is expected to witness significant growth owing to expanding healthcare infrastructure, increasing investments in pharmaceutical research, and rising awareness regarding blood-related disorders.
Why Invest in the Thrombin Market Outlook 2031
✅ Strong market growth driven by increasing trauma and surgical cases
✅ Rising prevalence of inherited blood coagulation disorders
✅ Growing pharmaceutical R&D investments
✅ Increasing adoption of advanced coagulation therapies
✅ Expanding healthcare infrastructure in emerging economies
👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=19580<ype=S
FAQs
- What is the projected market size by 2031?
The thrombin market is expected to reach US$ 1.1 Bn by 2031.
- What is the CAGR of the market?
The market is projected to grow at a CAGR of 6.1% from 2023 to 2031.
- What factors are driving market growth?
Rising road accidents, increasing blood coagulation disorders, and growing pharmaceutical R&D activities are major growth drivers.
- Which region dominates the market?
North America dominates due to advanced healthcare infrastructure and higher treatment adoption.
- What are the major trends in the market?
Key trends include innovation in thrombin therapies, expansion of clinical research, and increasing demand for surgical hemostatic solutions.
More Trending Reports by Transparency Market Research –
Parenteral Nutrition Market: https://www.transparencymarketresearch.com/parenteral-nutrition-market.html
Abortion Drugs Market: https://www.transparencymarketresearch.com/abortion-drugs-market.html
Oral Proteins and Peptides Market: https://www.transparencymarketresearch.com/oral-proteins-peptides-market.html
Barth Syndrome Therapeutics Market: https://www.transparencymarketresearch.com/barth-syndrome-therapeutics-market.html
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Media Contact:Â
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com
Leave a Reply